Inflammopharmacological Perspectives in Gout: Clinical Response Evaluation, Drug Safety, and Emerging Therapeutic Strategies

Abstract

Gout is a persistent inflammatory arthritis resulting from monosodium urate crystals deposition due to hyperuricemia, resulting in recurrent attacks, joint damage and serious systemic comorbidities. This review article offers a thorough review of the molecular and immunological pathophysiology of gout, focusing on purine metabolism, urate transport regulation, inflammasome activation and inflammatory signalling pathways. Although significant progress has been made in the field of arthritis, allowing for a better understanding of the disease mechanisms, the traditional treatment protocols have remained a source of significant challenges in terms of adverse effects and clinical resistance in complex patients. The article also reviews the current diagnostic methods of gout, including synovial fluid analysis, imaging studies and new biomarkers, in the context of evaluating therapeutic response and monitoring disease activity. In addition a comprehensive review of pharmacotherapy for acute and chronic gout attacks is offered, including the safety and efficacy profiles of nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, urate-lowering agents, biologic agents and recombinant uricases. Special attention is paid to adverse effects, possible drug interactions, and the limitations of treatments that impact long-term disease management. Finally, the review article also examines new approaches to therapy, including new xanthine oxidase inhibitors and plant-derived phytochemicals with anti-inflammatory and uric acid-lowering activities, which may provide safer alternatives or complementary approaches to traditional treatments. Through the integration of clinical outcomes, pharmacological mechanisms and new therapeutic approaches. This article provides a view on gouty arthritis to help promote personalized treatment approaches for gout and hyperuricemia.